Skip to main content

Diagnos: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ADK)

AI-generated - The Globe and Mail - Tue Jul 9, 7:54PM CDT

Diagnos is now ranked among the top 10 undervalued stocks in the Healthcare sector on the TSX Venture Exchange.

  • A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
  • Valuation methodology provided by Stockcalc (see below)

Stocks in this category are held primarily for capital appreciation.

SymbolNameClose Price ($)Valuation ($)DifferenceAverage Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
ADKDiagnos--- (0.0%)0.00.00.0
AQSAequus Pharmaceuticals--- (0.0%)0.00.00.0
ARCARCpoint--- (0.0%)0.00.00.0
ARCHArch Biopartners--- (0.0%)0.00.00.0
ASGAurora Spine--- (0.0%)0.00.00.0
AVCRAvricore Health--- (0.0%)0.00.00.0
BTIBioasis Technologies--- (0.0%)0.00.00.0
CANBCanadaBis Cap--- (0.0%)0.00.03.3
CHSComprehensive Healthcare--- (0.0%)0.00.00.0
COVCovalon Technologies--- (0.0%)0.00.00.0

All data provided as of July 09, 2024.
The list is sorted by stocks with the greatest percentage difference between valuation and price.

Diagnos

Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, UAE, Saudi Arabia, Mexico, Costa Rica, and others. The company's key revenue is derived from Canada.

Diagnos is listed under ADK on the TSX Venture Exchange.

Stockcalc

StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.

Stockcalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:

  • Discounted Cash Flow (DCF)
  • Price & Other Comparables
  • Multiples
  • Adjusted Book Value (ABV)
  • Analyst Consensus

Artificial Intelligence at Report on Business

Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.